Cerecor Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cerecor (CERC) Reports Q1 Loss of $0.12
May 11, 2018 8:17 AM EDTCerecor (NASDAQ: CERC) reported Q1 EPS of ($0.12).
The first quarter reflects an exciting pivot of Cerecor to an integrated biopharmaceutical company with a recently established and growing portfolio of pediatric commercial products as well as an equally important and growing pipeline of transformational assets, said Peter Greenleaf, Chief Executive Officer of Cerecor. We are pleased with the results of our investment in Cerecors development platform highlighted by the critical milestone of obtaining clearance for... More
